February 2026
M	T	W	T	F	S	S
	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

Arterial Disease Across Vascular Beds․ Lipoprotein(a) as a Causal Risk Factor

Pablo Corral/LinkedIn

Jan 16, 2026, 04:52

Arterial Disease Across Vascular Beds․ Lipoprotein(a) as a Causal Risk Factor

Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared on X:

”Lipoprotein(a) [Lp(a)] is not just about coronary disease.

Robust genetic and population data confirm Lp(a) as a causal risk factor across multiple vascular beds.

Peripheral Arterial Disease (PAD): Rising Lp(a) levels show a clear, stepwise association with PAD risk—up to ~3-fold higher risk at extreme concentrations.
Major Adverse Limb Events (MALE): In patients with PAD, high Lp(a) markedly increases the risk of amputations and repeat revascularizations.
Abdominal Aortic Aneurysm (AAA): Elevated Lp(a) is consistently associated with higher AAA risk, supported by Mendelian randomization.
Inflammation matters—but doesn’t negate Lp(a) risk: Lp(a)-associated cardiovascular risk persists independently of hsCRP levels, in both primary and secondary prevention.

Clinical takeaway: Lp(a) identifies residual vascular risk beyond LDL-C and traditional factors—supporting routine measurement and future targeted therapy.

Phase 3 Lp(a)-lowering outcome trials may redefine prevention across coronary and non-coronary vascular disease.

Open Access here.

Article:Lipoprotein(a) in cardiovascular disease with focus on peripheral arterial disease, major adverse limb events, abdominal aortic aneurysms and interaction with low-grade inflammation

Authors: Peter E. Thomas, Signe Vedel-Krogh, Pia R. Kamstrup, Børge G. Nordestgaard

Arterial Disease